AbbVie Inc. (ABBV)
NYSE · Healthcare · Drug Manufacturers - General
Profile
AbbVie Inc.
- Exchange
- NYSE
- Ticker
- ABBV
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Key facts
AbbVie Inc.: key facts
- AbbVie Inc. (NYSE: ABBV) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, AbbVie Inc. reported revenue of $61.2B and net income of $4.2B.
- Revenue grew 2.1% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $64.4B and net income was $6.3B.
MonkScore
AbbVie Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 64 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth50–60
- Profitability70–80
- Quality70–80
- Market Conviction90–100
- Safety90–100
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
AbbVie Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $64.4B | $61.2B | $56.3B | $54.3B | $58.1B | $56.2B |
| Gross profit | $46.0B | $43.0B | $39.4B | $33.9B | $40.6B | $38.8B |
| Operating income | $18.9B | $20.1B | $9.1B | $12.8B | $18.1B | $17.9B |
| Net income | $6.3B | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B |
| Operating cash flow | $19.5B | $19.0B | $18.8B | $22.8B | $24.9B | $22.8B |
| Capital expenditure | -$1.3B | -$1.2B | -$974.0M | -$777.0M | -$695.0M | -$787.0M |
| Free cash flow | $18.2B | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B |
| Total debt | $70.8B | $69.1B | $67.8B | $60.1B | $64.2B | $77.6B |
| Cash | $6.6B | $5.2B | $5.5B | $12.8B | $9.2B | $9.7B |
Revenue growth a year
- 1-year
- 8.6%
- 3-year
- 1.8%
- 4-year
- 2.1%
Compound growth between fiscal years.
Peers
Similar companies
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
Free tools for AbbVie Inc.: Dividend calculator
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.